Clonapilep (Clonapilep) is a benzodiazepine. Clonapilep affects chemicals in the brain that may be unbalanced. Clonapilep is also a seizure medicine, also called an anti-epileptic drug.
Clonapilep is used to treat certain seizure disorders (including absence seizures or Lennox-Gastaut syndrome) in adults and children.
Clonapilep is also used to treat panic disorder (including agoraphobia) in adults.
Clonapilep indications
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
sponsored
Seizure Disorders
Clonapilep is useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic and myoclonic seizures. In patients with absence seizures (petit mal) who have failed to respond to succinimides, Clonapilep may be useful.
In some studies, up to 30% of patients have shown a loss of anticonvulsant activity, often within 3 months of administration. In some cases, dosage adjustment may reestablish efficacy.
Panic Disorder
Clonapilep is indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-V. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks.
The efficacy of Clonapilep was established in two 6-to 9-week trials in panic disorder patients whose diagnoses corresponded to the DSM-IIIR category of panic disorder.
Panic disorder (DSM-V) is characterized by recurrent unexpected panic attacks, ie, a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes.
The effectiveness of Clonapilep in long-term use, that is, for more than 9 weeks, has not been systematically studied in controlled clinical trials. The physician who elects to use Clonapilep for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient.
How should I use Clonapilep?
Use Clonapilep orally disintegrating tablets as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Take Clonapilep orally disintegrating tablets by mouth with or without food.
Do not remove the blister from the outer pouch until you are ready to take Clonapilep orally disintegrating tablets. Make sure that your hands are dry when you open the blister pack. Do not push the tablet through the foil. Peel back the foil on the blister pack and place the tablet on your tongue. The tablet dissolves quickly and can be swallowed with saliva. Take Clonapilep orally disintegrating tablets with water. Take the tablet immediately after opening the blister pack. Do not store the removed tablet for future use
If you are taking Clonapilep orally disintegrating tablets for the prevention of seizures, taking Clonapilep orally disintegrating tablets at the same times each day will help you remember to take it.
Continue to take Clonapilep orally disintegrating tablets even if you feel well. Do not miss any doses. Clonapilep orally disintegrating tablets works best when there is a constant level of Clonapilep orally disintegrating tablets in your body.
If you miss a dose of Clonapilep orally disintegrating tablets and you are taking it regularly, take it as soon as possible. If several hours have passed or if it is nearing time for the next dose, do not double the dose to catch up, unless advised by your health care provider. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Clonapilep orally disintegrating tablets.
Uses of Clonapilep in details
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
sponsored
Use: Labeled Indications
Panic disorder: Treatment of panic disorder, with or without agoraphobia.
Seizure disorders: Mono- or adjunctive therapy in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic, and myoclonic seizures; absence seizures (petit mal) unresponsive to succinimides.
Off Label Uses
Bipolar disorder, manic or mixed episodes
Data from a meta-analysis of 5 randomized, controlled trials supports the use of Clonapilep in the treatment of acute bipolar mania. Additional data may be necessary to further define the role of Clonapilep in this condition.
Based on the American Academy of Neurology guideline for the treatment of tardive syndromes, Clonapilep given for tardive dyskinesia is probably effective in decreasing tardive dyskinesia symptoms in the short-term (approximately 3 months) and is suggested for the short-term treatment of tardive dyskinesia.
Tic disorders
Data from a limited number of patients studied in a single-blind and two retrospective studies suggest that Clonapilep may be beneficial for multifocal tic disorder or Tourette disorder. Additional data may be necessary to further define the role of Clonapilep in these conditions.
Clonapilep description
sponsored
Clonapilep is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one.
Clonapilep dosage
Clonapilep Dosage
Generic name: Clonapilep 0.5mg
Dosage form: tablets
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Clonapilep is available as a tablet. The tablets should be administered with water by swallowing the tablet whole.
Seizure Disorders
Adults
The initial dose for adults with seizure disorders should not exceed 1.5 mg/day divided into three doses. Dosage may be increased in increments of 0.5 to 1 mg every 3 days until seizures are adequately controlled or until side effects preclude any further increase. Maintenance dosage must be individualized for each patient depending upon response. Maximum recommended daily dose is 20 mg.
The use of multiple anticonvulsants may result in an increase of depressant adverse effects. This should be considered before adding Clonapilep to an existing anticonvulsant regimen.
Pediatric Patients
Clonapilep is administered orally. In order to minimize drowsiness, the initial dose for infants and children (up to 10 years of age or 30 kg of body weight) should be between 0.01 and 0.03 mg/kg/day but not to exceed 0.05 mg/kg/day given in two or three divided doses. Dosage should be increased by no more than 0.25 to 0.5 mg every third day until a daily maintenance dose of 0.1 to 0.2 mg/kg of body weight has been reached, unless seizures are controlled or side effects preclude further increase. Whenever possible, the daily dose should be divided into three equal doses. If doses are not equally divided, the largest dose should be given before retiring.
Geriatric Patients
There is no clinical trial experience with Clonapilep in seizure disorder patients 65 years of age and older. In general, elderly patients should be started on low doses of Clonapilep and observed closely.
Panic Disorder
Adults
The initial dose for adults with panic disorder is 0.25 mg bid. An increase to the target dose for most patients of 1 mg/day may be made after 3 days. The recommended dose of 1 mg/day is based on the results from a fixed dose study in which the optimal effect was seen at 1 mg/day. Higher doses of 2, 3 and 4 mg/day in that study were less effective than the 1 mg/day dose and were associated with more adverse effects. Nevertheless, it is possible that some individual patients may benefit from doses of up to a maximum dose of 4 mg/day, and in those instances, the dose may be increased in increments of 0.125 to 0.25 mg bid every 3 days until panic disorder is controlled or until side effects make further increases undesired. To reduce the inconvenience of somnolence, administration of one dose at bedtime may be desirable.
Treatment should be discontinued gradually, with a decrease of 0.125 mg bid every 3 days, until the drug is completely withdrawn.
There is no body of evidence available to answer the question of how long the patient treated with Clonapilep should remain on it. Therefore, the physician who elects to use Clonapilep for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient.
Pediatric Patients
There is no clinical trial experience with Clonapilep in panic disorder patients under 18 years of age.
Geriatric Patients
There is no clinical trial experience with Clonapilep in panic disorder patients 65 years of age and older. In general, elderly patients should be started on low doses of Clonapilep and observed closely.
Effect Of Clonapilep On The Pharmacokinetics Of Other Drugs
Clonapilep does not appear to alter the pharmacokinetics of phenytoin, carbamazepine or phenobarbital. The effect of Clonapilep on the metabolism of other drugs has not been investigated.
Effect Of Other Drugs On The Pharmacokinetics Of Clonapilep
Literature reports suggest that ranitidine, an agent that decreases stomach acidity, does not greatly alter Clonapilep pharmacokinetics.
In a study in which the 2 mg Clonapilep orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of Clonapilep was 10% lower and the Cmax of Clonapilep was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.
Fluoxetine does not affect the pharmacokinetics of Clonapilep. Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce Clonapilep metabolism, causing an approximately 30% decrease in plasma Clonapilep levels. Although clinical studies have not been performed, based on the involvement of the cytochrome P-450 3A family in Clonapilep metabolism, inhibitors of this enzyme system, notably oral antifungal agents, should be used cautiously in patients receiving Clonapilep.
Pharmacodynamic Interactions
The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
Clonapilep is well tolerated hematologically and is without renal, hepatic or gastrointestinal effects. Clinical trials with Clonapilep have shown it to have no toxic effect on the organs, even when given for long periods.
The adverse effects observed are referable to the sedative and muscle-relaxant effect of Clonapilep and consist above all of fatigue, somnolence, occasional muscular hypotonia and coordination disturbances. These effects are generally transitory and disappear spontaneously as treatment continues. They tend to occur early in treatment and can to a certain extent be avoided by progressive increase of dosage.
Clonapilep may give rise to salivatory or bronchial hypersecretion in infants and small children; supervision is thus required to ensure that the airways remain free. The effect of Clonapilep on behavioural disturbances in epileptic patients is generally favourable. In certain cases, however, aggressiveness, irritability or agitation may arise during treatment. Although Clonapilep has rarely been known to provoke a generalized seizure or to activate preexisting seizures, its association with other antiepileptics may be called for.
You should not use this medication if you have severe liver disease, of if you are allergic to Clonapilep or to other benzodiazepines, such as alprazolam (Xanax), chlordiazepoxide (Librium), clorazepate (Tranxene), diazepam (Valium), lorazepam (Ativan), or oxazepam (Serax).
Clonapilep may cause harm to an unborn baby, and may cause breathing or feeding problems in a newborn. But having seizures during pregnancy could harm both mother and baby. Do not start or stop taking Clonapilep during pregnancy without medical advice.
You may have thoughts about suicide while taking this medication. Your doctor will need to check you at regular visits. Do not miss any scheduled appointments. Call your doctor at once if you have any new or worsening symptoms such as: mood or behavior changes, depression, anxiety, or if you feel agitated, irritable, hostile, aggressive, restless, hyperactive (mentally or physically), or have thoughts about suicide or hurting yourself.
Before you take Clonapilep, tell your doctor if you have kidney or liver disease, glaucoma, any breathing problems, or a history of depression, suicidal thoughts, or addiction to drugs or alcohol.
Do not drink alcohol while taking Clonapilep. This medication can increase the effects of alcohol.
Clonapilep may be habit-forming and should be used only by the person it was prescribed for. Keep the medication in a secure place where others cannot get to it.
DailyMed. "CLONAZEPAM: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
The results of a survey conducted on ndrugs.com for Clonapilep are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Clonapilep. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
User reports
1 consumer reported useful
Was the Clonapilep drug useful in terms of decreasing the symptom or the disease? According to the reports released by ndrugs.com website users, the below mentioned percentages of users say the drug is useful / not useful to them in decreasing their symptoms/disease. The usefulness of the drug depends on many factors, like severity of the disease, perception of symptom, or disease by the patient, brand name used [matters only to a certain extent], other associated conditions of the patient. If the drug is not effective or useful in your case, you need to meet the doctor to get re-evaluated about your symptoms/disease, and he will prescribe an alternative drug.
Users
%
Useful
1
100.0%
Consumer reported price estimates
No survey data has been collected yet
Consumer reported time for results
No survey data has been collected yet
Consumer reported age
No survey data has been collected yet
Consumer reviews
There are no reviews yet. Be the first to write one!
